Jian Cui1, Gang Wang1, Amit D Kandhare2, Anwesha A Mukherjee-Kandhare2, Subhash L Bodhankar3. 1. Department of Neurosurgery, Xi'an No.1 Hospital, No. 30 South Street Powder Lane, Beilin District, Xi'an, Shaanxi Province, 710002, China. 2. Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, 411 038, India. 3. Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, 411 038, India. Electronic address: drslbodh@gmail.com.
Abstract
BACKGROUND: Huntington's disease (HD) is a complex multifactorial neurodegenerative disorder. Naringin, a flavanone glycoside exhibits potent anti-inflammatory and antiapoptotic effect. AIM: To evaluate the effect of naringin in quinolinic acid (QA)-induced neurotoxicity in laboratory rats. METHODS: Neurotoxicity was induced in male Wistar rats by single intrastriatal injection of QA (300 nmol/4 μl saline) in striatum except non-treated. Rats were administered orally with either vehicle (distilled water (10 mL/kg) or naringin (20, 40 and 80 mg/kg) or pioglitazone (40 mg/kg, p.o.) or its combination for 28 days. RESULTS: Naringin (40 and 80 mg/kg) treatment significantly (p < 0.05) attenuated QA-induced alterations in locomotor activity, rearing, grooming, neurological score, footprint analysis, grip strength and a number of slips. QA-induced altered striatal oxido-nitrosative stress (superoxide dismutase, glutathione, malondialdehyde and nitric oxide), neuroinflammatory markers (TNF-α, IL's and NF-kB mRNA) and apoptotic markers (Bax-Bcl-2, Caspase-3, and PPAR-γ mRNA) were significantly attenuated by (p < 0.05) by naringin. It also significantly increased (p < 0.05) mitochondrial complex (I-IV) activity. TTC scanning also showed that naringin treatment significantly reduced (p < 0.05) QA-induced striatal degeneration. It also significantly decreased (p < 0.05) OVA-induced elevated striatal apoptosis revealed by flow-cytometric analysis. CONCLUSION: Naringin exerts its neuroprotective effect against QA-induced neurotoxicity via modulation of oxido-nitrosative stress, neuroinflammatory, apoptotic markers and mitochondrial complex activity. Thus, it may offer a better therapeutic alternative for the management of HD like symptoms.
BACKGROUND:Huntington's disease (HD) is a complex multifactorial neurodegenerative disorder. Naringin, a flavanone glycoside exhibits potent anti-inflammatory and antiapoptotic effect. AIM: To evaluate the effect of naringin in quinolinic acid (QA)-induced neurotoxicity in laboratory rats. METHODS:Neurotoxicity was induced in male Wistar rats by single intrastriatal injection of QA (300 nmol/4 μl saline) in striatum except non-treated. Rats were administered orally with either vehicle (distilled water (10 mL/kg) or naringin (20, 40 and 80 mg/kg) or pioglitazone (40 mg/kg, p.o.) or its combination for 28 days. RESULTS:Naringin (40 and 80 mg/kg) treatment significantly (p < 0.05) attenuated QA-induced alterations in locomotor activity, rearing, grooming, neurological score, footprint analysis, grip strength and a number of slips. QA-induced altered striatal oxido-nitrosative stress (superoxide dismutase, glutathione, malondialdehyde and nitric oxide), neuroinflammatory markers (TNF-α, IL's and NF-kB mRNA) and apoptotic markers (Bax-Bcl-2, Caspase-3, and PPAR-γ mRNA) were significantly attenuated by (p < 0.05) by naringin. It also significantly increased (p < 0.05) mitochondrial complex (I-IV) activity. TTC scanning also showed that naringin treatment significantly reduced (p < 0.05) QA-induced striatal degeneration. It also significantly decreased (p < 0.05) OVA-induced elevated striatal apoptosis revealed by flow-cytometric analysis. CONCLUSION:Naringin exerts its neuroprotective effect against QA-induced neurotoxicity via modulation of oxido-nitrosative stress, neuroinflammatory, apoptotic markers and mitochondrial complex activity. Thus, it may offer a better therapeutic alternative for the management of HD like symptoms.
Authors: Xianli Yao; Li Li; Amit D Kandhare; Anwesha A Mukherjee-Kandhare; Subhash L Bodhankar Journal: Exp Ther Med Date: 2019-12-13 Impact factor: 2.447
Authors: Alberto Hernandez-Leon; Gabriel Fernando Moreno-Pérez; Martha Martínez-Gordillo; Eva Aguirre-Hernández; María Guadalupe Valle-Dorado; María Irene Díaz-Reval; María Eva González-Trujano; Francisco Pellicer Journal: Molecules Date: 2021-12-16 Impact factor: 4.411